CD8A and neoplasm: Additionally, IHC revealed that the combination of anti-PD-1 and PRMT5i synergistically reduced Ki-67 levels in Renca tumor cells while increasing markers of tumor-infiltrating immune cells, including CD3, CD8a, and granzyme B (Fig. 7J and Fig. S7B).